<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222480</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FHC-CT-201-BZ</org_study_id>
    <nct_id>NCT02222480</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide</brief_title>
  <official_title>A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in Combination With Hydrochlorothiazide in Patients With Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the
      Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in
      Combination with Hydrochlorothiazide in Patients with Mild to Moderate Hypertension
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of treatment in 24-hour mean systolic blood pressure (SBP) using ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>from baseline to 2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan/Hydrochlorothiazide 60/25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan/Hydrochlorothiazide 120/25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_label>Fimasartan 60 mg, Hydrochlorothiazide 25 mg</arm_group_label>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg</arm_group_label>
    <arm_group_label>Fimasartan 120 mg, Hydrochlorothiazide 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects of no childbearing potential 19-70 years of age

          2. Mean clinic-measured sitting DBP (siDBP) of 90-109 mmHg and mean clinic-measured
             sitting SBP (siSBP) of 140-179 mmHg after a ≥1-week washout of prior antihypertensive
             medications (no wash-out is needed for those not on any antihypertensive medications)
             with a difference of ≤10 mmHg in sitting DBP between before and after run-in

          3. Subjects who agree to participate in this study and give written informed consent

          4. Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

        Exclusion Criteria:

          1. Severe hypertension, i.e., mean siDBP ≥110 mmHg or mean siSBP ≥180 mmHg

          2. Orthostatic hypotension with clinically significant signs or symptoms

          3. Secondary hypertension

          4. Not able to stop administration other antihypertensive medications than the study
             drugs (i.e., fimasartan and hydrochlorothiazide) throughout the entire study period

          5. Clinically significant abnormal laboratory test results, e.g., serum creatinine &gt;1.5
             times upper limit of normal, AST, ALT &gt; 2 times upper limit of normal

          6. Conditions that may affect to absorption, distribution, metabolism, and excretion for
             the study drugs

          7. Severe insulin-dependent or uncontrolled diabetes mellitus (HbA1c &gt;9%, increased dose
             of an oral hypoglycemic agent within 12 weeks before screening, or active insulin
             treatment at screening)

          8. Severe cardiovascular diseases within 6 months of screening including ischemic heart
             disease, peripheral vascular disease, significant ventricular tachycardia, atrial
             fibrillation, atrial flutter or other significant arrhythmia, hypertrophic obstructive
             cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis,
             hemodynamically significant aortic valve or mitral valve disease, severe
             cerebrovascular disease

          9. History of percutaneous transluminal coronary angiography or coronary artery bypass
             graft

         10. Chronic debilitating disease, autoimmune disease, connective tissue disease

         11. Positive on serum hepatitis B surface antigen, anti-hepatitis C virus antibody, or
             anti-HIV antibody

         12. History or evidence of alcohol or drug abuse within 2 years

         13. Known allergic reaction to any angiotensin receptor blockers

         14. Chronic inflammation disease requiring chronic anti-inflammation therapy

         15. Women of childbearing potential without any contraceptive measure or breast-feeding
             mother

         16. Prior participation in a clinical trial of any investigational products within 12
             weeks from screening

         17. Serum potassium &lt;3.5 mmol/L or &gt;5.5 mmol/L at any time of the study period

         18. Depletion of sodium ion or body fluid, which cannot be corrected easily during the
             study period

         19. Evidence of hereditary disease, including galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption.

         20. Considered unsuitable to participate in the study under the discretion of the
             principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients</keyword>
  <keyword>with mild</keyword>
  <keyword>moderate</keyword>
  <keyword>essential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

